Verona Pharma Announces FDA Response to End-of-Phase 2 Briefing Package for Ensifentrine in COPD and Outlines Phase 3 ENHANCE Clinical Program

• NASDAQ: $VRNA
• Notified: $3.98
• 02:01 EDT